About Imipridones

Chimerix is developing a new class of selective cancer therapies called imipridones. These drugs target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which potentially enables broad therapeutic use for cancer and other diseases through selective modulation of distinct downstream mechanisms.


  • ONC201 for brain and other cancers
  • ONC206 for central nervous system cancer
  • ONC212 for pancreatic cancer and leukemia